|
US2014228303A1
|
|
Novel sglt inhibitors
|
|
US2013302383A1
|
|
Liquid oral composition of lanthanum salts
|
|
WO2012053006A2
|
|
Improved oral fast dissolving films comprising combination of polymers and method of preparation thereof
|
|
WO2012035549A2
|
|
An improved process for the synthesis of beta amino acid derivatives
|
|
WO2010106557A2
|
|
Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof
|
|
US2012010158A1
|
|
Tumor necrosis factor inhibiting peptides and uses thereof
|
|
WO2010038241A2
|
|
Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
|
|
WO2010029571A2
|
|
Modified release ramipril compositions and uses thereof
|
|
WO2009050726A2
|
|
Compositions and methods for improved delivery of bupropion
|
|
US2008086377A1
|
|
Method and system for managing customers during peak or busy hours for restaurants and other industries
|
|
US2008113455A1
|
|
Planar etching of dissimilar materials
|
|
US2007299054A1
|
|
Oral pharmaceutical composition of a poorly water-soluble active agent
|
|
WO2007110876A2
|
|
Novel sulfonanilide derivatives, pharmaceutical compositions comprising the same and process thereof
|
|
WO2007072503A2
|
|
Combinations for managing inflammation and associated disorders
|
|
US2006159748A1
|
|
Oral immediate release formulation of a poorly water-soluble active substance
|
|
US2008050434A1
|
|
Novel Composition for Topical Delivery
|
|
WO2005065640A1
|
|
Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions
|
